Skip to main content
NASDAQ:FNCH

Finch Therapeutics Group Competitors

$13.02
+0.98 (+8.14 %)
(As of 05/18/2021 03:45 AM ET)
Add
Compare
Today's Range
$12.62
$13.36
50-Day Range
$12.03
$17.51
52-Week Range
$11.56
$22.50
Volume1,428 shs
Average Volume141,292 shs
Market Capitalization$613.83 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Finch Therapeutics Group (NASDAQ:FNCH) Vs. NUVB, SEER, IBRX, IMCR, BCAB, and EWTX

Should you be buying FNCH stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Finch Therapeutics Group, including Nuvation Bio (NUVB), Seer (SEER), ImmunityBio (IBRX), Immunocore (IMCR), BioAtla (BCAB), and Edgewise Therapeutics (EWTX).

Finch Therapeutics Group (NASDAQ:FNCH) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Profitability

This table compares Finch Therapeutics Group and Nuvation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Finch Therapeutics GroupN/AN/AN/A
Nuvation BioN/AN/AN/A

Earnings & Valuation

This table compares Finch Therapeutics Group and Nuvation Bio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics GroupN/AN/AN/AN/AN/A
Nuvation BioN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Finch Therapeutics Group and Nuvation Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Finch Therapeutics Group00303.00
Nuvation Bio00603.00

Finch Therapeutics Group presently has a consensus price target of $29.3333, indicating a potential upside of 125.29%. Nuvation Bio has a consensus price target of $17.40, indicating a potential upside of 46.10%. Given Finch Therapeutics Group's higher probable upside, research analysts clearly believe Finch Therapeutics Group is more favorable than Nuvation Bio.

Finch Therapeutics Group (NASDAQ:FNCH) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Profitability

This table compares Finch Therapeutics Group and Seer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Finch Therapeutics GroupN/AN/AN/A
SeerN/AN/AN/A

Earnings & Valuation

This table compares Finch Therapeutics Group and Seer's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics GroupN/AN/AN/AN/AN/A
SeerN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Finch Therapeutics Group and Seer, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Finch Therapeutics Group00303.00
Seer02202.50

Finch Therapeutics Group presently has a consensus price target of $29.3333, indicating a potential upside of 125.29%. Seer has a consensus price target of $66.3333, indicating a potential upside of 115.23%. Given Finch Therapeutics Group's stronger consensus rating and higher probable upside, research analysts clearly believe Finch Therapeutics Group is more favorable than Seer.

Summary

Finch Therapeutics Group beats Seer on 3 of the 3 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares ImmunityBio and Finch Therapeutics Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunityBioN/AN/AN/A
Finch Therapeutics GroupN/AN/AN/A

Valuation and Earnings

This table compares ImmunityBio and Finch Therapeutics Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBioN/AN/AN/AN/AN/A
Finch Therapeutics GroupN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for ImmunityBio and Finch Therapeutics Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunityBio00103.00
Finch Therapeutics Group00303.00

ImmunityBio presently has a consensus target price of $25.00, indicating a potential upside of 51.98%. Finch Therapeutics Group has a consensus target price of $29.3333, indicating a potential upside of 125.29%. Given Finch Therapeutics Group's higher possible upside, analysts clearly believe Finch Therapeutics Group is more favorable than ImmunityBio.

Summary

Finch Therapeutics Group beats ImmunityBio on 2 of the 2 factors compared between the two stocks.

Immunocore (NASDAQ:IMCR) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares Immunocore and Finch Therapeutics Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunocoreN/AN/AN/A
Finch Therapeutics GroupN/AN/AN/A

Valuation and Earnings

This table compares Immunocore and Finch Therapeutics Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunocoreN/AN/AN/AN/AN/A
Finch Therapeutics GroupN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Immunocore and Finch Therapeutics Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunocore01202.67
Finch Therapeutics Group00303.00

Immunocore presently has a consensus target price of $54.3333, indicating a potential upside of 44.89%. Finch Therapeutics Group has a consensus target price of $29.3333, indicating a potential upside of 125.29%. Given Finch Therapeutics Group's stronger consensus rating and higher possible upside, analysts clearly believe Finch Therapeutics Group is more favorable than Immunocore.

Summary

Finch Therapeutics Group beats Immunocore on 3 of the 3 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares BioAtla and Finch Therapeutics Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioAtlaN/AN/AN/A
Finch Therapeutics GroupN/AN/AN/A

Valuation and Earnings

This table compares BioAtla and Finch Therapeutics Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtlaN/AN/AN/AN/AN/A
Finch Therapeutics GroupN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for BioAtla and Finch Therapeutics Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioAtla00403.00
Finch Therapeutics Group00303.00

BioAtla presently has a consensus target price of $62.75, indicating a potential upside of 37.01%. Finch Therapeutics Group has a consensus target price of $29.3333, indicating a potential upside of 125.29%. Given Finch Therapeutics Group's higher possible upside, analysts clearly believe Finch Therapeutics Group is more favorable than BioAtla.

Edgewise Therapeutics (NASDAQ:EWTX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares Edgewise Therapeutics and Finch Therapeutics Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edgewise TherapeuticsN/AN/AN/A
Finch Therapeutics GroupN/AN/AN/A

Valuation and Earnings

This table compares Edgewise Therapeutics and Finch Therapeutics Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edgewise TherapeuticsN/AN/AN/AN/AN/A
Finch Therapeutics GroupN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Edgewise Therapeutics and Finch Therapeutics Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edgewise Therapeutics01302.75
Finch Therapeutics Group00303.00

Edgewise Therapeutics presently has a consensus target price of $34.25, indicating a potential upside of 27.32%. Finch Therapeutics Group has a consensus target price of $29.3333, indicating a potential upside of 125.29%. Given Finch Therapeutics Group's stronger consensus rating and higher possible upside, analysts clearly believe Finch Therapeutics Group is more favorable than Edgewise Therapeutics.

Summary

Finch Therapeutics Group beats Edgewise Therapeutics on 2 of the 2 factors compared between the two stocks.


Finch Therapeutics Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Nuvation Bio logo
NUVB
Nuvation Bio
2.1$11.35+4.9%$2.18 billionN/A0.00Analyst Upgrade
News Coverage
Gap Up
SEER
Seer
1.1$31.71+2.8%$1.88 billionN/A0.00Analyst Report
IBRX
ImmunityBio
1.7$16.45+0.9%$1.81 billionN/A0.00News Coverage
Gap Up
Immunocore logo
IMCR
Immunocore
1.3$38.00+1.3%$1.62 billionN/A0.00Analyst Revision
News Coverage
Gap Down
BioAtla logo
BCAB
BioAtla
1.7$46.80+2.1%$1.54 billionN/A0.00Earnings Announcement
EWTX
Edgewise Therapeutics
1.8$27.45+2.0%$1.28 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.4$29.51+3.9%$1.23 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$26.26+1.6%$1.15 billionN/A0.00
KNTE
Kinnate Biopharma
1.7$26.00+10.6%$1.01 billionN/A0.00News Coverage
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$28.44+0.2%$994.39 millionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
CNTB
Connect Biopharma
1.7$16.22+1.2%$932.72 millionN/A0.00
STEM
Stem
0.0$20.29+4.1%$932.59 millionN/A0.00Gap Up
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$24.83+0.4%$875.42 millionN/A0.00Earnings Announcement
Gap Up
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.4$12.14+9.0%$815.97 millionN/A0.00Earnings Announcement
News Coverage
Pharming Group logo
PHAR
Pharming Group
0.0$12.11+0.0%$776.60 millionN/A0.00
FDMT
4D Molecular Therapeutics
1.3$27.50+2.2%$717.80 millionN/A0.00Earnings Announcement
Vor Biopharma logo
VOR
Vor Biopharma
1.5$19.57+2.1%$711.08 millionN/A0.00
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.3$19.13+2.9%$674.61 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.5$21.50+3.7%$659.09 millionN/A0.00
VACC
Vaccitech
0.3$16.93+0.4%$579.09 millionN/A0.00Gap Up
Inventiva logo
IVA
Inventiva
1.4$14.75+3.7%$569.79 millionN/A0.00
ACHL
Achilles Therapeutics
1.6$13.33+0.9%$546.37 millionN/A0.00Gap Up
Nanobiotix logo
NBTX
Nanobiotix
0.9$15.65+1.2%$521.77 millionN/A0.00
VECT
VectivBio
1.6$14.95+7.9%$508.52 millionN/A0.00Quiet Period Expiration
Gap Down
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$11.05+13.0%$475.14 millionN/A0.00
Landos Biopharma logo
LABP
Landos Biopharma
1.5$12.42+6.0%$468.18 millionN/A0.00Earnings Announcement
News Coverage
Gap Down
BMEA
Biomea Fusion
1.7$16.04+1.1%$461.44 millionN/A0.00Analyst Report
News Coverage
SGTX
Sigilon Therapeutics
1.4$13.65+3.6%$430.38 millionN/A0.00
RAIN
Rain Therapeutics
1.3$16.60+3.8%$414.73 millionN/A0.00Analyst Report
Insider Buying
News Coverage
Gap Up
MIGI
Mawson Infrastructure Group
0.0$0.85+4.7%$413.38 millionN/A0.00Upcoming Earnings
Gap Down
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
1.7$16.60+1.4%$411.30 millionN/A0.00Gap Up
NexImmune logo
NEXI
NexImmune
1.7$17.83+0.2%$409.19 millionN/A0.00Earnings Announcement
News Coverage
Angion Biomedica logo
ANGN
Angion Biomedica
1.6$13.82+1.7%$407.47 millionN/A0.00Earnings Announcement
News Coverage
PRTG
Portage Biotech
0.0$27.61+4.3%$333.61 millionN/A0.00Gap Down
HOWL
Werewolf Therapeutics
0.3$11.87+0.8%$329.64 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
1.9$9.20+1.1%$278.35 millionN/A0.00Earnings Announcement
Analyst Downgrade
Analyst Revision
Gap Down
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.5$6.65+2.6%$275.52 millionN/A-2.63
IMPL
Impel NeuroPharma
1.3$13.89+1.9%$269.67 millionN/A0.00Analyst Report
News Coverage
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$4.43+0.9%$240.81 millionN/A-2.36Earnings Announcement
Analyst Upgrade
VINC
Vincerx Pharma
1.0$16.42+2.7%$229.62 millionN/A0.00Earnings Announcement
RPHM
Reneo Pharmaceuticals
2.0$7.90+1.5%$191.27 millionN/A0.00Quiet Period Expiration
Annovis Bio logo
ANVS
Annovis Bio
1.7$26.60+3.2%$190.70 millionN/A0.00
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
1.8$6.68+2.2%$162.61 millionN/A0.00Earnings Announcement
Gap Down
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$7.50+0.5%$144.53 millionN/A0.00Gap Down
LBPH
Longboard Pharmaceuticals
1.9$9.02+3.0%$118.88 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$7.42+16.7%$118.65 millionN/A0.00Gap Up
Trading Halted
GANX
Gain Therapeutics
1.7$9.79+1.8%$116.24 millionN/A0.00News Coverage
LGVN
Longeveron
0.0$5.29+0.2%$100.28 millionN/A0.00
UPC
Universe Pharmaceuticals
0.0$3.19+1.6%$69.38 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$17.47+0.3%$68.27 millionN/A0.00
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.